Phosphocreatine protects endothelial cells from Methylglyoxal induced oxidative stress and apoptosis via the regulation of PI3K/Akt/eNOS and NF-κB pathway

Vascul Pharmacol. 2017 Apr:91:26-35. doi: 10.1016/j.vph.2016.08.012. Epub 2016 Aug 30.

Abstract

Methylglyoxal (MGO), an active metabolite of glucose, can cause cellular injury which has an affinity for the progression of diabetes-associated atherosclerosis. Phosphocreatine (PCr) is a well-known high-energy phosphate compound. However, its protective effects and mechanism in the formation of a diabetes-associated atherosclerosis have not been clarified. In the present study, we investigated whether PCr could prevent MGO-induced apoptosis in human umbilical vascular endothelial cells (HUVECs) and explored the possible mechanisms. Cells were pre-treated with PCr and then stimulated with MGO. Cell morphology, cytotoxicity and apoptosis were assessed by light microscopy, MTT assay, and Annexin V-FITC respectively. Apoptotic-related proteins were evaluated by Western blotting. Reactive oxygen species (ROS) generation, intracellular calcium and mitochondrial membrane potential (MMP) were measured with fluorescent probes. Our results showed that PCr dose-dependently prevented MGO associated HUVEC cytotoxicity and suppressed MGO activated ROS generation as well as apoptotic biochemical changes such as lactate dehydrogenase, malondialdehyde leakage, loss of MMP, decreased Bcl-2/Bax protein ratio, levels of caspase-3 and 9. In addition, the antiapoptotic effect of PCr enhanced p-Akt/Akt protein ratio, NO synthase (eNOS) activation, NO production and cGMP levels and also was partially suppressed by a PI3K inhibitor (LY294002). Furthermore, PCr also inhibited MGO-induced transcriptional activity of Nuclear factor kappa B (NFκB). In conclusion, our data described that PCr exerts an antiapoptotic effect in HUVECs exposed to oxidative stress by MGO through the mitochondrial pathway and the modulation of PI3K/Akt/eNOS and NF-κB signaling pathway. Thus, it might be a candidate therapeutic agent for diabetic-associated cardiovascular diseases.

Keywords: Apoptosis; Endothelial cells; Methylglyoxal; Oxidative stress; Phosphocreatine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / pharmacology*
  • Apoptosis / drug effects*
  • Apoptosis Regulatory Proteins / metabolism
  • Cells, Cultured
  • Cytoprotection
  • Dose-Response Relationship, Drug
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • NF-kappa B / metabolism*
  • Nitric Oxide Synthase Type III / metabolism*
  • Oxidative Stress / drug effects*
  • Phosphatidylinositol 3-Kinase / metabolism*
  • Phosphocreatine / pharmacology*
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Pyruvaldehyde / toxicity*
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects

Substances

  • Antioxidants
  • Apoptosis Regulatory Proteins
  • NF-kappa B
  • Reactive Oxygen Species
  • Phosphocreatine
  • Pyruvaldehyde
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt